You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 5, May 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Radioimmunotherapy of Human Colon Cancer in Nude Mice

Robert R. Buras, MD; Barbara G. Beatty, PhD; Lawrence E. Williams, PhD; Philip M. Wanek, RPh; James B. Harris, MD; L. Robert Hill, PhD; J. David Beatty, MD

Arch Surg. 1990;125(5):660-664.


Abstract

• Nude mice bearing subcutaneous human colon cancer xenografts (LS174T) were treated with 120 µCi of yttrium 90—labeled anti-carcinoembryonic antigen monoclonal antibodies (specific therapy), 120 µCi of90Y-labeled anti-melanoma monoclonal antibodies (nonspecific therapy), or phosphate-buffered saline solution (no treatment control). Mean (±SD) tumor growth rates (percent increase per day) over the first 30 days of the study were as follows: 0.6%±0.2% per day (specific therapy); 17.7%±5.7% per day (nonspecific therapy); and 30.5%±4.2% per day (control). In all three groups, tumors over 1 g had similar doubling times (5.74±0.71 d). Specific therapy caused a lag in tumor growth corresponding to a 3-logarithm cell kill. Estimated tumor dose of radiation obtained by tissue analysis was 34 and 14 Gy for specific and nonspecific therapy, respectively. In conclusion, 120 µCi of90Y-labeled anti-carcinoembryonic antigen monoclonal antibodies was effective in suppressing growth of human colon cancer xenografts. Clinical studies with this preparation are recommended.

(Arch Surg. 1990;125:660-664)



Author Affiliations

From the Department of General Oncologic Surgery (Drs Buras, B. G. Beatty, Harris, and J. D. Beatty), the Division of Diagnostic Radiology (Dr Williams), and the Department of Biostatistics (Dr Hill), City of Hope National Medical Center, Duarte, Calif; and Hybritech Inc, San Diego, Calif (Mr Wanek).


Footnotes

Accepted for publication August 12, 1989.

Reprint requests to the Department of General Oncologic Surgery, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010 (Dr J. D. Beatty).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.